Vizgen operates in the field of spatial genomics, focusing on high-resolution imaging to analyze biological samples at the cellular and subcellular levels. Its main product, MERSCOPE, utilizes MERFISH chemistry to collect detailed spatial data, which is particularly beneficial for research in immuno-oncology, helping scientists understand tumor and immune interactions in various cancers. In addition to MERSCOPE, Vizgen provides a Gene Panel Design Portal that assists researchers in creating custom gene panels for their studies, and a tool called VPT for cell segmentation that outlines cell boundaries and produces single-cell data. Unlike its competitors, Vizgen combines advanced imaging technology with user-friendly applications, making it easier for researchers to conduct complex analyses. The company's goal is to enhance the understanding of biological systems through spatial genomics, ultimately contributing to advancements in cancer research and treatment.

Blue Water Life Science

Sofina

Novalis Lifesciences

Tao Capital Partners

David R. Walt

ARCH Venture Partners

Northpond Ventures

Pura Vida Investments

Biotechnology

Healthcare

Vizgen

Vizgen launches Certified Service Provider (CSP) Program, expanding access to single-cell spatial genomics technology.

Vizgen Launches Certified Service Provider (CSP) Program, Expanding Access to Single-Cell Spatial Genomics Technology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University. The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation. The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations. Despite strenuous objections from 10x and Harvard, the Court approved Vizgen’s request to amend the claims to include additional antitrust allegations relating to 10x’s anticompetitive economic practices. These new allegations bolster Vizgen’s existing antitrust counterclaims against both 10x and Harvard, accusing them of conspiring to monopolize the market and obstructing Vizgen’s ability to compete globally

Vizgen Announces Significant Win In Ongoing Patent Litigation Against 10X Genomics And Harvard University

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample. "This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape," said Terry Lo, CEO, Vizgen, Inc. "It is another patent underscoring Vizgen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health," he said

Vizgen Issued A New Us Patent For Its Merfish Technology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry at the AACR 2024 Annual Meeting. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year. The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm2 of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform

Vizgen Expands Single-Cell Spatial Transcriptomics Offering With Introduction Of Merscope® Ultra Platform And Merfish 2.0 Chemistry At Aacr 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, is very pleased to announce that, on March 7, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied 10x Genomics Inc.’s petition to institute an Inter Partes Review proceeding (IPR) against U.S. Patent 11,098,303 B2 (‘303 Patent), which Vizgen licenses exclusively from Harvard University. This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation. In its decision denying the institution of an IPR of the ‘303 Patent, the PTAB noted that 10x’s petition was deficient under the law and did not demonstrate “a reasonable likelihood that [10x] would prevail with respect to at least 1 of the claims challenged in the petition.” The denial of petition IPR2023-01299, which is available here, represents a crucial win for Vizgen. In C.A. No

Vizgen Announces Denial Of 10X Genomics’ Petition For Inter Partes Review Of Vizgen-Licensed Patent Currently Asserted Against 10X’S Xenium Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a significant capital raise to fuel its continued growth and execution of long-term vision. At the same time, the company has also taken steps to streamline its operations and reduce headcount. These measures come in response to unlawful monopolistic conduct by 10x Genomics and Harvard University, Vizgen’s own licensor—including baseless patent litigation in the U.S. and Europe. Despite being the target of anticompetitive legal claims, Vizgen remains fully committed to its mission of providing the industry’s best tools for single-cell spatial biology and driving discoveries aimed at improving human health. With the new funding, Vizgen continues to invest in the development of its groundbreaking technologies, ensuring a long-term commitment to support its customers

With Capital Raise, Vizgen Commits To Its Long-Term Success And Defense Against Baseless Anti-Competitive Legal Actions

During AGBT 2024, Vizgen announced 2024 product roadmap highlights including enhanced chemistry updates and the launch of the MERSCOPE 1000-plex Gene Panels.

With Capital Raise, Vizgen Commits to Its Long-term Success and Defense Against Baseless Anti-Competitive Legal Actions

ScaleBio is partnering with Vizgen to give the scientific community more options to combine single-cell and spatial technologies for integrated data analysis.

Scale Biosciences Unveils Platform for Dramatic Scaling of Single-Cell Experiments and Announces Partnerships to Drive Ease of Use and Enable New Biological Insights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap. In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week. The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research. Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024. Vizgen’s high sensitivity was recently emphasized in a recent study conducted by the New York Genome Center. The study, “Comparative analysis of multiplexed in situ gene expression profiling technologies,” published on bioRxiv found that Vizgen’s MERSCOPE® Platform has the best performance in a comparison of six spatial transcriptomics technologies, including the highest sensitivity as well as excellent specificity and accuracy in cell segmentation

Vizgen Kicks Off Agbt With Enhanced Merfish Chemistry Updates And 2024 Product Roadmap Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida. As part of the strategic partnership, Vizgen and ScaleBio will leverage their respective technology to generate high resolution data from serial mouse brain tissue sections for single cell RNA-seq, single cell DNA methylation and targeted spatial gene expression. They will also be able to demonstrate the measurements from single cell RNA-seq, targeted spatial gene expression profiling and single nuclei DNA methylation to identify matching cell types, including all major cell types in the brain and subtypes of neurons. “The unique combination of our technology and that of ScaleBio is capable of powering deep analysis to uncover a tissue’s composition and the roles and interactions of heterogeneous cell types within that tissue. Such data can then be leveraged for a variety of applications, including neuroscience and cancer biology,” said Terry Lo, President and CEO of Vizgen. “We are committed to providing the scientific community with essential spatial tools and technologies to drive impactful discoveries, and our collaboration with ScaleBio has the potential to drive transformative advances in the field.”

Vizgen And Scale Biosciences Unveil Strategic Partnership At Agbt

Biotechnology for spatial genomics research

Vizgen

Biotechnology for spatial genomics research

Vizgen

Biotechnology for spatial genomics research

About

Simplify's Take

What believers are saying

What critics are saying

What makes Vizgen unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

There are no jobs for Vizgen right now.